Type 1 Diabetes (T1D) Clinical Trials

Find Type 1 Diabetes (T1D) Clinical Trials Near You

A Digital Mindfulness and Biometric Feedback Application for Young Adults With Type 1 Diabetes

Status: Recruiting
Location: See location...
Intervention Type: Behavioral
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

The purpose of this research study is to test a mindfulness app called Calm Health among young adults with type 1 diabetes or other absolute insulin deficiency diabetes. Mindfulness is the practice of being aware of your thoughts and feelings in the moment without judgment or negative reaction. All participants will receive mindfulness guidance and personalized feedback about the relationship among your mindfulness, blood sugar, stress, and sleep.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 30
Healthy Volunteers: f
View:

• Receiving diabetes care at Yale New Haven Children's Hospital or Yale New Haven Hospital.

• Sign and date informed consent form we will provide

• Willingness to complete procedures and availability for duration of the study

• Aged 18-30 years

• Diagnosed with type 1 diabetes (T1D) or other absolute insulin deficiency diabetes (latent autoimmune diabetes of adulthood, diabetes secondary to pancreatitis) for at least 1 year.

• User of a continuous glucose monitor (CGM) in your routine clinical care for at least the past 2 weeks.

• Able to use a smartphone.

• Able to read and write English.

Locations
United States
Connecticut
Yale University School of Medicine
RECRUITING
New Haven
Contact Information
Primary
Laura M Nally, MD
laura.nally@yale.edu
203-785-5831
Time Frame
Start Date: 2026-02-04
Estimated Completion Date: 2026-09
Participants
Target number of participants: 10
Treatments
Experimental: Mindfulness App
Use the mindfulness app for 6 weeks, wear an actigraphy watch, share the data from your own continuous glucose monitor (CGM), answer surveys and interviews about the app.
Sponsors
Leads: Yale University
Collaborators: Calm.com, Inc.

This content was sourced from clinicaltrials.gov